Published in Neuropsychopharmacology on March 25, 2009
Hormonal mechanisms of cooperative behaviour. Philos Trans R Soc Lond B Biol Sci (2010) 1.18
The acute and subchronic effects of a brain-penetrating, neurotensin-1 receptor agonist on feeding, body weight and temperature. Neuropharmacology (2009) 0.93
Reduced levels of vasopressin and reduced behavioral modulation of oxytocin in psychotic disorders. Schizophr Bull (2014) 0.91
The neurotensin-1 receptor agonist PD149163 inhibits conditioned avoidance responding without producing catalepsy in rats. Eur Neuropsychopharmacol (2011) 0.86
Arginine vasotocin regulation of interspecific cooperative behaviour in a cleaner fish. PLoS One (2012) 0.83
Social interaction and social withdrawal in rodents as readouts for investigating the negative symptoms of schizophrenia. Eur Neuropsychopharmacol (2013) 0.82
Promise and pitfalls of animal models of schizophrenia. Curr Psychiatry Rep (2010) 0.82
Neurobiology of sociability. Adv Exp Med Biol (2012) 0.82
Clozapine and PD149163 elevate prepulse inhibition in Brown Norway rats. Behav Neurosci (2011) 0.82
Systemic administration of the neurotensin NTS₁-receptor agonist PD149163 improves performance on a memory task in naturally deficient male brown Norway rats. Exp Clin Psychopharmacol (2014) 0.81
Further characterization of the predictive validity of the Brattleboro rat model for antipsychotic efficacy. J Psychopharmacol (2010) 0.80
Effects of the neurotensin NTS₁ receptor agonist PD149163 on visual signal detection in rats. Eur J Pharmacol (2013) 0.79
Repeated effects of the neurotensin receptor agonist PD149163 in three animal tests of antipsychotic activity: assessing for tolerance and cross-tolerance to clozapine. Pharmacol Biochem Behav (2014) 0.78
Song in an Affiliative Context Relates to the Neural Expression of Dopamine- and Neurotensin-Related Genes in Male European Starlings. Brain Behav Evol (2016) 0.76
Patterns of Spontaneous Local Network Activity in Developing Cerebral Cortex: Relationship to Adult Cognitive Function. PLoS One (2015) 0.75
Electroencephalographic and early communicative abnormalities in Brattleboro rats. Physiol Rep (2013) 0.75
Transplantation of mesenchymal stem cells reverses behavioural deficits and impaired neurogenesis caused by prenatal exposure to valproic acid. Oncotarget (2017) 0.75
Atypical Social Development in Vasopressin-Deficient Brattleboro Rats. eNeuro (2016) 0.75
Differential effects of antipsychotics on lateral bias and social attention in female rats. Psychopharmacology (Berl) (2012) 0.75
Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"? Schizophr Bull (2000) 9.62
A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia. Schizophr Bull (2005) 4.66
Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology (Berl) (2001) 4.52
The neurocognitive effects of low-dose haloperidol: a two-year comparison with risperidone. Biol Psychiatry (2002) 2.70
Profound impairment in social recognition and reduction in anxiety-like behavior in vasopressin V1a receptor knockout mice. Neuropsychopharmacology (2004) 2.26
A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int J Neuropsychopharmacol (2005) 2.10
First episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol. Schizophr Res (2004) 2.06
Cognitive deficits as treatment targets in schizophrenia. Schizophr Res (2004) 1.86
One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia. Schizophr Res (2005) 1.73
Cognitive impairment and functional outcome in schizophrenia and bipolar disorder. J Clin Psychiatry (2006) 1.69
The social deficits of the oxytocin knockout mouse. Neuropeptides (2002) 1.54
Social discrimination procedure: an alternative method to investigate juvenile recognition abilities in rats. Physiol Behav (1995) 1.43
A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: opening a closed book. Biol Psychiatry (2004) 1.39
Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large long-term trial. Am J Psychiatry (2005) 1.34
Predicting drug efficacy for cognitive deficits in schizophrenia. Schizophr Bull (2005) 1.28
Social motivation is reduced in vasopressin 1b receptor null mice despite normal performance in an olfactory discrimination task. Horm Behav (2004) 1.19
Atypical antipsychotics attenuate a sub-chronic PCP-induced cognitive deficit in the novel object recognition task in the rat. Behav Brain Res (2007) 1.15
Microdialysis administration of vasopressin into the septum improves social recognition in Brattleboro rats. Physiol Behav (1994) 1.13
Reversal of sensorimotor gating deficits in Brattleboro rats by acute administration of clozapine and a neurotensin agonist, but not haloperidol: a potential predictive model for novel antipsychotic effects. Neuropsychopharmacology (2004) 1.11
The "delayed onset" of antipsychotic action--an idea whose time has come and gone. J Psychiatry Neurosci (2006) 1.10
Novel antipsychotic-like effects on prepulse inhibition of startle produced by a neurotensin agonist. J Pharmacol Exp Ther (1999) 1.09
Aripiprazole ameliorates phencyclidine-induced impairment of recognition memory through dopamine D1 and serotonin 5-HT1A receptors. Psychopharmacology (Berl) (2008) 1.08
The effects of chronic administration of established and putative antipsychotics on natural prepulse inhibition deficits in Brattleboro rats. Behav Brain Res (2007) 1.06
Developing predictive animal models and establishing a preclinical trials network for assessing treatment effects on cognition in schizophrenia. Schizophr Bull (2005) 1.04
Habituation deficits induced by metabotropic glutamate receptors 2/3 receptor blockade in mice: reversal by antipsychotic drugs. J Pharmacol Exp Ther (2006) 1.02
On the trail of a cognitive enhancer for the treatment of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry (2005) 1.01
A systemically administered neurotensin agonist blocks disruption of prepulse inhibition produced by a serotonin-2A agonist. Neuropsychopharmacology (2002) 1.00
Current therapy issues and unmet clinical needs in the treatment of schizophrenia: a review of the new generation antipsychotics. Int Clin Psychopharmacol (2005) 0.98
Effects of a neurotensin analogue (PD149163) and antagonist (SR142948A) on the scopolamine-induced deficits in a novel object discrimination task. Behav Pharmacol (2006) 0.97
Neurotensin receptors: binding properties, transduction pathways, and structure. Cell Mol Neurobiol (1995) 0.97
The neurotensin agonist PD149163 increases Fos expression in the prefrontal cortex of the rat. Neuropsychopharmacology (2004) 0.95
Novel treatments of schizophrenia: targeting the neurotensin system. CNS Neurol Disord Drug Targets (2006) 0.93
Selectively increased trace conditioning under the neurotensin agonist PD 149163 in an aversive procedure in which SR 142948A was without intrinsic effect. J Psychopharmacol (2008) 0.89
Vasopressin-deficient rats exhibit sensorimotor gating deficits that are reversed by subchronic haloperidol. Biol Psychiatry (2001) 0.88
SSR181507, a dopamine D(2) receptor antagonist and 5-HT(1A) receptor agonist, alleviates disturbances of novelty discrimination in a social context in rats, a putative model of selective attention deficit. Psychopharmacology (Berl) (2005) 0.88
The effects of neuroleptics on neuropsychological test results of schizophrenics. Arch Clin Neuropsychol (1988) 0.86
Short-term cognitive improvement in schizophrenics treated with typical and atypical neuroleptics. Neuropsychobiology (2002) 0.85
Differential attenuation of d-amphetamine-induced disruption of conditional discrimination performance by dopamine and serotonin antagonists. Psychopharmacology (Berl) (2006) 0.84
Preclinical investigations into the antipsychotic potential of the novel histamine H3 receptor antagonist GSK207040. Psychopharmacology (Berl) (2008) 0.84
Upregulation of striatal dopamine-2 receptors in Brattleboro rats with prepulse inhibition deficits. Biol Psychiatry (2006) 0.83
Early onset of antipsychotic response in the treatment of acutely agitated patients with psychotic disorders. Schizophr Res (2008) 0.83
Permeability of the blood-brain barrier to the neurotensin8-13 analog NT1. Brain Res (1995) 0.82
Antipsychotic-induced suppression of locomotion in juvenile, adolescent and adult rats. Eur J Pharmacol (2007) 0.82
Pharmacological treatment to augment hole board habituation in prenatal Vitamin D-deficient rats. Behav Brain Res (2005) 0.79
A neurotensin agonist and antagonist decrease and increase activity, respectively, but do not preclude discrete cue conditioning. J Psychopharmacol (2008) 0.79
The effect of neuroleptic treatments on executive function and symptomatology in schizophrenia: a 1-year follow up study. Schizophr Res (2005) 0.79
Behavioral differences between vasopressin-deficient (Brattleboro) and normal Long-Evans rats. Peptides (1984) 0.79
The vasopressin precursor in the Brattleboro (di/di) rat. Int J Pept Protein Res (1988) 0.79
Null mutation of the arginine-vasopressin gene in rats slows attentional engagement and facilitates response accuracy in a lateralized reaction time task. Neuropsychopharmacology (2003) 0.78
A comparison of the learning abilities of Brattleboro rats with hereditary diabetes insipidus and Long-Evans rats using positively reinforced operant conditioning. Prog Brain Res (1983) 0.78
Altered emotionality of the vasopressin-deficient Brattleboro rat. Peptides (1985) 0.77
Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. Nat Genet (2013) 8.02
Genome-wide association of bipolar disorder suggests an enrichment of replicable associations in regions near genes. PLoS Genet (2011) 1.23
Reversal of sensorimotor gating deficits in Brattleboro rats by acute administration of clozapine and a neurotensin agonist, but not haloperidol: a potential predictive model for novel antipsychotic effects. Neuropsychopharmacology (2004) 1.11
The effects of chronic administration of established and putative antipsychotics on natural prepulse inhibition deficits in Brattleboro rats. Behav Brain Res (2007) 1.06
The reversal of amphetamine-induced locomotor activation by a selective neurotensin-1 receptor agonist does not exhibit tolerance. Psychopharmacology (Berl) (2008) 1.01
A systemically administered neurotensin agonist blocks disruption of prepulse inhibition produced by a serotonin-2A agonist. Neuropsychopharmacology (2002) 1.00
The acute and subchronic effects of a brain-penetrating, neurotensin-1 receptor agonist on feeding, body weight and temperature. Neuropharmacology (2009) 0.93
Altered extracellular dopamine concentration in the brains of cholecystokinin-A receptor deficient rats. Neurosci Lett (2003) 0.92
The effects of oxytocin and its analog, carbetocin, on genetic deficits in sensorimotor gating. Eur Neuropsychopharmacol (2011) 0.84
Fronto-temporal-mesolimbic gene expression and heritable differences in amphetamine-disrupted sensorimotor gating in rats. Psychopharmacology (Berl) (2012) 0.84
Evidence for association of bipolar disorder to haplotypes in the 22q12.3 region near the genes stargazin, IFT27 and parvalbumin. Am J Med Genet B Neuropsychiatr Genet (2012) 0.83
Upregulation of striatal dopamine-2 receptors in Brattleboro rats with prepulse inhibition deficits. Biol Psychiatry (2006) 0.83
Clozapine and PD149163 elevate prepulse inhibition in Brown Norway rats. Behav Neurosci (2011) 0.82
Promise and pitfalls of animal models of schizophrenia. Curr Psychiatry Rep (2010) 0.82
Genome-wide significant association between a 'negative mood delusions' dimension in bipolar disorder and genetic variation on chromosome 3q26.1. Transl Psychiatry (2012) 0.78
Effects of neurotensin-2 receptor deletion on sensorimotor gating and locomotor activity. Behav Brain Res (2010) 0.77
Alkyne-containing chelating ligands: synthesis, properties and metal coordination of 1,2-di(quinolin-8-yl)ethyne. Dalton Trans (2006) 0.75